CTRI/2017/12/010803暂停2 期
A Phase II / III, prospective, randomised, active-controlled, open label, Parallel group, 2-arm, Multi-centric trial for evaluation of Efficacy, Safety, and Tolerability of DTaP plus Hib (Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b) combination vaccine in Indian paediatric population in comparison with Pentaxim® (Diphtheria, acellular Pertussis, Tetanus, Hemophilus influenza b and IPV) combination vaccine of Sanofi Pasteur
试验速览
- 阶段
- 2 期
- 状态
- 暂停
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Full term (>=37 weeks) Indian children of either gender who have attained age >= 6 weeks
- •2. Subjects who are healthy as established by medical history & clinical examination and are eligible to receive primary immunization as per Universal Immunization Programme (UIP).
- •3. Parent or LAR of subject willing to give written informed consent and to comply to all study related procedures
排除标准
- •1.Pre-term or Low birth weight children (<= 2.5 kg at birth)
- •2.History of hypersensitivity to any of vaccines or vaccine components
- •3.History of any seizure / neurological or neuro-psychological disorder
- •4.Presence of congenital disorder /congenital infections or primary/acquired immuno-deficiency syndrome
- •5.Children with family history of congenital or hereditary immunodeficiency
- •6.History of exposure to immunosuppressive therapy after birth
- •7.History of HIV or HBV infection in the mother
- •8.Children who received blood or blood-derived products before enrolment
- •9.History of diphtheria, tetanus, pertussis, or Hemophilus influenza disease before enrolment or history of vaccination against diphtheria, tetanus, pertussis, or Hemophilus influenza
- •10.Planned administration of any other vaccine not foreseen by the study protocol within the period 30 days before inclusion or 30 days after the last dose of the vaccine except Rotavirus Vaccine, hepatitis B vaccine, Pneumococcal Conjugate Vaccine, Polio vaccine and any other vaccine given as a part of the national immunization schedule, allowed at that time of the study period.
- •11.Evidence of any chronic illness that could interfere with vaccine administration or evaluation
- •12.Planned or elective surgery during the study period.
- •13.Children suffering from acute febrile ( > 38°C) illness / or acute non-febrile systemic illness in the past one week.
- •14.Children with thrombocytopenia/ bleeding disorder / any medical condition contraindicating intramuscular injections
- •15.Children diagnosed of blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
- •16.Concurrent participation in any other trial at any time during the study period
- •17.Any other condition, which in the opinion of the investigator might interfere with the trial conduct and completion
研究者
相似试验
已完成
2 期
Rivaroxaban in Antiphospholipid Syndrome (RAPS)Thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosusMusculoskeletal DiseasesISRCTN68222801niversity College London (UK)156
进行中（未招募）
1 期
Comparison of rivaroxaban (Xarelto®; Bayer HealthCare), fixed-dose oral anticoagulant (blood thinner), versus warfarin in patients with antiphospholipid syndrome (called APS), with or without 'lupus' (systemic lupus erythematosus)Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE).MedDRA version: 14.1 Level: PT Classification code 10002817 Term: Antiphospholipid syndrome System Organ Class: 10021428 - Immune system disordersEUCTR2012-002345-38-GBniversity College London116
已完成
3 期
on-inferiority trial using carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage in women delivering vaginallyCTRI/2016/05/006969World Health Organization7,098
进行中（未招募）
1 期
Carbetocin for preventing excessive bleeding after birth.EUCTR2014-004445-26-GBWorld Health Organization30,000
已完成
3 期
A clinical trial to study the safety and the consistency in terms of protection between three production lots of the PsA-TT conjugate vaccine produced at large scale in the 5 to 10 years of age.CTRI/2009/091/000368Serum Institute of India Limited830